Working... Menu
Trial record 55 of 566 for:    "Polycystic Ovary Syndrome"

Plasma Levels of GDF-9 and GDF-15 in Patients With Polycystic Ovary Syndrome.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01644305
Recruitment Status : Completed
First Posted : July 19, 2012
Last Update Posted : June 27, 2018
Information provided by (Responsible Party):
Zehra Berberoglu, Ankara Education and Research Hospital

Brief Summary:
The purpose of this study is to determine the plasma levels of GDF-9 and GDF-15, and their association with bone and cardiovascular parameters in patients with Polycystic Ovary Syndrome.

Condition or disease
Polycystic Ovary Syndrome

Layout table for study information
Study Type : Observational
Actual Enrollment : 85 participants
Observational Model: Case-Control
Time Perspective: Cross-Sectional
Official Title: 1. Association of Plasma GDF-9 or GDF-15 Levels With Bone Parameters in Polycystic Ovary Syndrome. 2. Plasma GDF-15 Levels and Their Association With Hormonal and Metabolic Status in Women With Polycystic Ovary Syndrome Aged 25-35.
Actual Study Start Date : July 2012
Actual Primary Completion Date : July 2013
Actual Study Completion Date : August 2013

Resource links provided by the National Library of Medicine

Polycystic Ovary Syndrome
Idiopathic hirsutism

Primary Outcome Measures :
  1. The association of GDF 9 AND GDF 15 with bone and cardiovascular parameters in women with polycystic ovary syndrome [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   25 Years to 35 Years   (Adult)
Sexes Eligible for Study:   Female
Sampling Method:   Probability Sample
Study Population
Hospital Endocrinology Outpatient Clinic

Inclusion Criteria:

  • Female patients at ages 25-35 diagnosed with polycystic ovarian syndrome and idiopathic hirsutism

Exclusion Criteria:

  • acute infectious disease, a thyroid, pituitary, nutritional, inflammatory, hepatic, renal, or neoplastic disorder; history of cardiovascular disease or pulmonary embolism; a family history of coronary artery disease; smoking history; hypertension; diabetes mellitus; use of oral contraceptives, anti-androgens and drugs known to interfere with cytokine release, such as corticosteroids, immunosuppressors, or nonsteroidal antiinflammatory drugs.

any medication known to affect hormonal or metabolic parameters.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01644305

Layout table for location information
Ankara Education and Research Hospital
Ankara, Turkey, 06340
Sponsors and Collaborators
Ankara Education and Research Hospital

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Zehra Berberoglu, Ass. Prof., Ankara Education and Research Hospital Identifier: NCT01644305     History of Changes
Other Study ID Numbers: 3849
First Posted: July 19, 2012    Key Record Dates
Last Update Posted: June 27, 2018
Last Verified: June 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Layout table for MeSH terms
Polycystic Ovary Syndrome
Pathologic Processes
Ovarian Cysts
Ovarian Diseases
Adnexal Diseases
Genital Diseases, Female
Gonadal Disorders
Endocrine System Diseases